المؤلفون: Camilla Nero, Luca Boldrini, Jacopo Lenkowicz, Maria Teresa Giudice, Alessia Piermattei, Frediano Inzani, Tina Pasciuto, Angelo Minucci, Anna Fagotti, Gianfranco Zannoni, Vincenzo Valentini, Giovanni Scambia

المصدر: International Journal of Molecular Sciences, Vol 23, Iss 19, p 11326 (2022)

مصطلحات موضوعية: ovarian cancer, somatic BRCA mutational status, digital pathology, machine learning, artificial intelligence, Biology (General), QH301-705.5, Chemistry, QD1-999

الوصف: BRCA 1/2 genes mutation status can already determine the therapeutic algorithm of high grade serous ovarian cancer patients. Nevertheless, its assessment is not sufficient to identify all patients with genomic instability, since BRCA 1/2 mutations are only the most well-known mechanisms of homologous recombination deficiency (HR-d) pathway, and patients displaying HR-d behave similarly to BRCA mutated patients. HRd assessment can be challenging and is progressively overcoming BRCA testing not only for prognostic information but more importantly for drugs prescriptions. However, HR testing is not already integrated in clinical practice, it is quite expensive and it is not refundable in many countries. Selecting patients who are more likely to benefit from this assessment (BRCA 1/2 WT patients) at an early stage of the diagnostic process, would allow an optimization of genomic profiling resources. In this study, we sought to explore whether somatic BRCA1/2 genes status can be predicted using computational pathology from standard hematoxylin and eosin histology. In detail, we adopted a publicly available, deep-learning-based weakly supervised method that uses attention-based learning to automatically identify sub regions of high diagnostic value to accurately classify the whole slide (CLAM). The same model was also tested for progression free survival (PFS) prediction. The model was tested on a cohort of 664 (training set: n = 464, testing set: n = 132) ovarian cancer patients, of whom 233 (35.1%) had a somatic BRCA 1/2 mutation. An area under the curve of 0.7 and 0.55 was achieved in the training and testing set respectively. The model was then further refined by manually identifying areas of interest in half of the cases. 198 images were used for training (126/72) and 87 images for validation (55/32). The model reached a zero classification error on the training set, but the performance was 0.59 in terms of validation ROC AUC, with a 0.57 validation accuracy. Finally, when applied to predict PFS, the model achieved an AUC of 0.71, with a negative predictive value of 0.69, and a positive predictive value of 0.75. Based on these analyses, we have planned further steps of development such as proving a reference classification performance, exploring the hyperparameters space for training optimization, eventually tweaking the learning algorithms and the neural networks architecture for better suiting this specific task. These actions may allow the model to improve performances for all the considered outcomes.

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/1422-0067/23/19/11326Test; https://doaj.org/toc/1661-6596Test; https://doaj.org/toc/1422-0067Test

الوصول الحر: https://doaj.org/article/3ed79ab49f9a401db82af0e094207f7aTest

المؤلفون: Daniela Gustinucci, Lucia Ciccocioppo, Luigi Coppola, Giovanni Negri, Gianfranco Zannoni, Basilio Passamonti, Elena Cesarini, Ciro Ianzano, Tiziana Andreano, Anjuta Pireddu, Paolo Giorgi-Rossi

المصدر: Diagnostics, Vol 11, Iss 4, p 619 (2021)

مصطلحات موضوعية: Hepika, HPV, carcinoma, CIN, precancerous lesion, cancer, Medicine (General), R5-920

الوصف: Objective: To evaluate the clinical accuracy of Hepika test to identify cancer/precancerous lesions of the uterine cervix. Materials and Methods: A multicentre retrospective study was carried out in 2018 and included 330 liquid-based cytology samples from three Italian centres of women aged 25–64 who had been tested for the human papillomavirus (HPV) and whose histology or follow-up outcome was known. Hepika is an enzyme-linked immunosorbent assay (ELISA) targeting the protein complexes E6#p53 and E7#pRb. After excluding samples without sufficient residual material, the clinical accuracy of Hepika test was evaluated in 274 samples: adenocarcinoma (ADC) (4), squamous cell carcinoma (SCC) (7), adenocarcinoma in situ (AIS) (1), cervical intraepithelial neoplasia (CIN) grade 3 (60), CIN2 (51), CIN1 (34), and negative histology (117). Association, sensitivity, and specificity for carcinoma, CIN3+ and CIN2+ are reported. Results: Positive Hepika test was associated with a high probability of carcinoma (odds ratio (DOR) = 33.68, 95% confidence interval (CI) 7.0–163.1); sensitivity was 81.8%, specificity, 88.2%. A positive Hepika test showed a weaker association with CIN3+ lesions (DOR = 3.5; 95% CI 1.75–6.99) and lower sensitivity (27.8%). Conclusion: The Hepika test was found to be an accurate biomarker for HPV-induced cervical carcinoma. Population-based prospective studies are needed to confirm the clinical usefulness of the Hepika test in the differential diagnosis of HPV-induced invasive lesions.

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2075-4418/11/4/619Test; https://doaj.org/toc/2075-4418Test

الوصول الحر: https://doaj.org/article/fe090b6a6fb344caaec081891d76cf28Test

المؤلفون: Khaled Gaballa, Carla Cicero, Valerio Gallotta, Gianfranco Zannoni, Giovanni Scambia

المصدر: Journal of the Egyptian National Cancer Institute, Vol 30, Iss 2, Pp 81-83 (2018)

مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: We discuss the diagnosis and the management of endometrial carcinoma in a single horn of bicornuate uterus in a 64-year-old woman as a case report. The case underwent laparoscopic radical hysterectomy and bilateral iliac lymphadenectomy.The gross examination of the uterus revealed a bicornuate uterus with a greater horn of 12 × 9 × 8 cm and a smaller horn of 10 × 3 cm. The cavity of the greater horn showed a neoplastic growth of 10 cm with infiltration of about 1,8 cm of the myometrium from whole thickness of 1.9 cm. while the other horn was free of tumor tissue.The microscopic examination of the uterus revealed G2 endometrioid adenocarcinoma of the endometrium of the greater horn with infiltration of more than 50% of the myometrium.In the presence of bicornuate uterus, a bilateral endometrial biopsy should be performed in order to reduce the risk of delayed or missed diagnosis.The management of a case of bicornuate unicollis uterus with endometrial carcinoma in only one horn is the same as patients with endometrial cancer in single uterus and depends mainly on stage and histological grade of the tumor.The possibility of existence of a separate uterine cavity should always be considered when endometrial cancer is clinically suspected but pathology fails to confirm the diagnosis. This points out the importance of a careful physical examination and radiographic evaluation in such cases. Keywords: Bicornuate uterus, Endometrial cancer

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S1110036218300256Test; https://doaj.org/toc/1110-0362Test

الوصول الحر: https://doaj.org/article/4824eb1fe0714d3f87dc0edb3064dafcTest

المؤلفون: Alexandros Rodolakis, Giovanni Scambia, François Planchamp, Maribel Acien, Attilio Di Spiezio Sardo, Martin Farrugia, Michael Grynberg, Maja Pakiz, Kitty Pavlakis, Nathalie Vermeulen, Gianfranco Zannoni, Ignacio Zapardiel, Kirsten Louise Tryde Macklon

المصدر: International Journal of Gynecologic Cancer. 33:208-223

مصطلحات موضوعية: Oncology, Automotive Engineering, Obstetrics and Gynecology, General Medicine

الوصف: STUDY QUESTION How should fertility-sparing treatment of patients with endometrial carcinoma be performed? SUMMARY ANSWER Forty-eight recommendations were formulated on fertility-sparing treatment of patients with endometrial carcinoma. WHAT IS KNOWN ALREADY The standard surgical treatment of endometrial carcinoma consisting of total hysterectomy with bilateral salpingo-oophorectomy drastically affects the quality of life of patients and creates a challenge for clinicians. Recent evidence-based guidelines of the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) provide comprehensive guidelines on all relevant issues of diagnosis and treatment in endometrial carcinoma in a multidisciplinary setting. While addressing also work-up for fertility preservation treatments and the management and follow-up for fertility preservation, it was considered relevant to further extend the guidance on fertility-sparing treatment. STUDY DESIGN, SIZE, DURATION A collaboration was set up between the ESGO, the European Society of Human Reproduction and Embryology (ESHRE) and the European Society for Gynaecological Endoscopy (ESGE), aiming to develop clinically relevant and evidence-based guidelines focusing on key aspects of fertility-sparing treatment in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide. PARTICIPANTS/MATERIALS, SETTING, METHODS ESGO/ESHRE/ESGE nominated an international multidisciplinary development group consisting of practising clinicians and researchers who have demonstrated leadership and expertise in the care and research of endometrial carcinoma (11 experts across Europe). To ensure that the guidelines are evidence-based, the literature published since 2016, identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgement was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 95 independent international practitioners in cancer care delivery and patient representatives. MAIN RESULTS AND THE ROLE OF CHANCE The multidisciplinary development group formulated 48 recommendations in four sections; patient selection, tumour clinicopathological characteristics, treatment and special issues. LIMITATIONS, REASONS FOR CAUTION Of the 48 recommendations, none could be based on level I evidence and only 16 could be based on level II evidence, implicating that 66% of the recommendations are supported only by observational data, professional experience and consensus of the development group. WIDER IMPLICATIONS OF THE FINDINGS These recommendations provide guidance to professionals caring for women with endometrial carcinoma, including but not limited to professionals in the field of gynaecological oncology, onco-fertility, reproductive surgery, endoscopy, conservative surgery and histopathology, and will help towards a holistic and multidisciplinary approach for this challenging clinical scenario. STUDY FUNDING/COMPETING INTEREST(S) All costs relating to the development process were covered from ESGO, ESHRE and ESGE funds. There was no external funding of the development process or manuscript production. G.S. has reported grants from MSD Italia S.r.l., advisory boards for Storz, Bayer, Astrazeneca, Metronic, TESARO Bio Italy S.r.l and Johnson & Johnson, and honoraria for lectures from Clovis Oncology Italy S.r.l. M.G. has reported advisory boards for Gedeon Richter and Merck. The other authors have reported no conflicts of interest. DISCLAIMER This document represents the views of ESHRE, ESGO and ESGE which are the result of consensus between the relevant stakeholders and where relevant based on the scientific evidence available at the time of preparation. The recommendations should be used for informational and educational purposes. They should not be interpreted as setting a standard of care, or be deemed inclusive of all proper methods of care nor exclusive of other methods of care reasonably directed to obtaining the same results. They do not replace the need for application of clinical judgement to each individual presentation, nor variations based on locality and facility type.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b432ab46dd33660d3bcef0f335f4cdf3Test
https://doi.org/10.1136/ijgc-2022-004047Test

المؤلفون: Luigi Carlo Turco, Luigi Pedone Anchora, Camilla Fedele, Frediano Inzani, Alessia Piermattei, Maurizio Martini, Mariaconcetta Volpe, Simona Marchetti, Rosaria Santangelo, Nicolò Bizzarri, Francesco Cosentino, Virginia Vargiu, Maria De Ninno, Gabriella Macchia, Vincenzo Valentini, Gianfranco Zannoni, Giovanni Scambia, Gabriella Ferrandina

المصدر: International Journal of Gynecologic Cancer. 33:489-497

مصطلحات موضوعية: Settore MED/40 - GINECOLOGIA E OSTETRICIA, Oncology, cervical cancer, Obstetrics and Gynecology, pathology, radiotherapy

الوصف: ObjectiveWhile human papillomavirus (HPV) has been shown to play a significant role in cervical cancer carcinogenesis (HPV associated cases), a considerable percentage of cervical cancers occur independently of HPV status (HPV independent).MethodsIn this retrospective study of 254 locally advanced cervical cancer patients treated with chemoradiotherapy and radical surgery, HPV genotypes were determined using the Anyplex II HPV28 kit that uses multiplex, real time polymerase chain reaction technology. The primary endpoints of this study were to evaluate the complete response to chemoradiotherapy (pathologic complete response), the presence of microscopic (<3 mm, pathologic micro partial response, group 1) and macroscopic (>3 mm, pathologic macro partial response, group 2) residual carcinoma in the cervix, and the persistence of metastatic lymph nodes (group 3) in HPV independent cervical cancers. Secondary endpoints were evaluation of disease-free survival and overall survival.ResultsOf 254 patients studied, 21 cases (8.3%) of cervical cancer were determined to be HPV independent. The percentage of pathologic complete response was found to be higher in the HPV associated group compared with the HPV independent group (pConclusionsThis study showed that HPV status at diagnosis could be a relevant factor for clinical outcomes in locally advanced cervical cancer patients.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24af9b08c508011395e1aea6590b773fTest
https://doi.org/10.1136/ijgc-2022-003940Test

المؤلفون: Giorgio Bogani, Isabelle Ray-Coquard, David Mutch, Ignace Vergote, Pedro T Ramirez, Jaime Prat, Nicole Concin, Natalie Yan Li Ngoi, Robert L Coleman, Takayuki Enomoto, Kazuhiro Takehara, Hannelore Denys, Domenica Lorusso, Masashi Takano, Satoru Sagae, Pauline Wimberger, Yakir Segev, Se Ik Kim, Jae-Weon Kim, Fernanda Herrera, Andrea Mariani, Rebecca A Brooks, David Tan, Biagio Paolini, Valentina Chiappa, Mariangela Longo, Francesco Raspagliesi, Pierluigi Benedetti Panici, Violante Di Donato, Giuseppe Caruso, Nicoletta Colombo, Sandro Pignata, Gianfranco Zannoni, Giovanni Scambia, Bradley J Monk

مصطلحات موضوعية: Biomedical and clinical sciences, Clinical sciences, Oncology and carcinogenesis, Science & Technology, Life Sciences & Biomedicine, Oncology, Obstetrics & Gynecology, Genital Neoplasms, Female, Gestational Trophoblastic Disease, LOW-DOSE METHOTREXATE, TROPHOBLASTIC-DISEASE, ACTINOMYCIN-D, FOLINIC ACID, SINGLE-AGENT, CLINICAL GUIDELINES, PD-L1 EXPRESSION, RISK, NEOPLASIA, MANAGEMENT, Pregnancy, Humans, Uterine Neoplasms, Treatment Outcome, Retrospective Studies, Choriocarcinoma, Cancer, Pediatric, Clinical Research, 6.1 Pharmaceuticals

الوصف: Gestational choriocarcinoma accounts for 5% of gestational trophoblastic neoplasms. Approximately 50%, 25%, and 25% of gestational choriocarcinoma occur after molar pregnancies, term pregnancies, and other gestational events, respectively. The FIGO scoring system categorizes patients into low (score 0 to 6) and high risk (score 7 or more) choriocarcinoma. Single-agent and multi-agent chemotherapy are used in low- and high-risk patients, respectively. Chemotherapy for localized disease has a goal of eradication of disease without surgery and is associated with favorable prognosis and fertility preservation. Most patients with gestational choriocarcinoma are cured with chemotherapy; however, some (<5.0%) will die as a result of multi-drug resistance, underscoring the need for novel approaches in this group of patients. Although there are limited data due to its rarity, the treatment response with immunotherapy is high, ranging between 50–70%. Novel combinations of immune checkpoint inhibitors with targeted therapies (including VEGFR-2 inhibitors) are under evaluation. PD-L1 inhibitors are considered a potential important opportunity for chemo-resistant patients, and to replace or de-escalate chemotherapy to avoid or minimize chemotherapy toxicity. In this review, the Rare Tumor Working Group and the European Organization for Research and Treatment of Cancer evaluated the current landscape and further perspective in the management of patients diagnosed with gestational choriocarcinoma.

العلاقة: http://hdl.handle.net/10779/DRO/DU:25584804.v1Test; https://figshare.com/articles/journal_contribution/Gestational_choriocarcinoma/25584804Test

الإتاحة: http://hdl.handle.net/10779/DRO/DU:25584804.v1Test
https://figshare.com/articles/journal_contribution/Gestational_choriocarcinoma/25584804Test

المؤلفون: Giorgio Bogani, Isabelle Ray-Coquard, Nicole Concin, Natalie Yan Li Ngoi, Philippe Morice, Giuseppe Caruso, Takayuki Enomoto, Kazuhiro Takehara, Hannelore Denys, Domenica Lorusso, Robert Coleman, Michelle M Vaughan, Masashi Takano, Diane Michele Provencher, Satoru Sagae, Pauline Wimberger, Robert Póka, Yakir Segev, Se Ik Kim, Jae-Weon Kim, Francisco Jose Candido dos Reis, Pedro T Ramirez, Andrea Mariani, Mario Leitao, Vicky Makker, Nadeem R Abu-Rustum, Ignace Vergote, Gianfranco Zannoni, David Tan, Mary McCormack, Biagio Paolini, Marta Bini, Francesco Raspagliesi, Pierluigi Benedetti Panici, Violante Di Donato, Ludovico Muzii, Nicoletta Colombo, Sandro Pignata, Giovanni Scambia, Bradley J Monk

المساهمون: Bogani, G, Ray-Coquard, I, Concin, N, Ngoi, N, Morice, P, Caruso, G, Enomoto, T, Takehara, K, Denys, H, Lorusso, D, Coleman, R, Vaughan, M, Takano, M, Provencher, D, Sagae, S, Wimberger, P, Póka, R, Segev, Y, Kim, S, Kim, J, Candido Dos Reis, F, Ramirez, P, Mariani, A, Leitao, M, Makker, V, Abu-Rustum, N, Vergote, I, Zannoni, G, Tan, D, Mccormack, M, Paolini, B, Bini, M, Raspagliesi, F, Benedetti Panici, P, Di Donato, V, Muzii, L, Colombo, N, Pignata, S, Scambia, G, Monk, B

مصطلحات موضوعية: female, Settore MED/40 - GINECOLOGIA E OSTETRICIA, Oncology, genital neoplasms, female, genital neoplasms, Obstetrics and Gynecology, carcinosarcoma, uterine cancer

الوصف: Endometrial carcinosarcoma is a rare and aggressive high-grade endometrial carcinoma with secondary sarcomatous trans-differentiation (conversion theory). The clinical presentation and diagnostic work-up roughly align with those of the more common endometrioid counterpart, although endometrial carcinosarcoma is more frequently diagnosed at an advanced stage. Endometrial carcinosarcoma is not a single entity but encompasses different histological subtypes, depending on the type of carcinomatous and sarcomatous elements. The majority of endometrial carcinosarcomas are characterized by p53 abnormalities. The proportion ofPOLEand microsatellite instablity-high (MSI-H) is directly related to the epithelial component, being approximately 25% and 3% in endometrioid and non-endometrioid components.The management of non-metastatic disease is based on a multimodal approach with optimal surgery followed by (concomitant or sequential) chemotherapy and radiotherapy, even for early stages. Palliative chemotherapy is recommended in the metastatic or recurrent setting, with carboplatin/paclitaxel doublet being the first-line regimen. Although the introduction of immunotherapy plus/minus a tyrosine kinase inhibitor shifted the paradigm of treatment of patients with recurrent endometrial cancer, patients with endometrial carcinosarcoma were excluded from most studies evaluating single-agent immunotherapy or the combination. However, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved the use of pembrolizumab and lenvatinib in endometrial cancer (all histotypes) after progression on chemotherapy and single-agent immunotherapy in MSI-H cancers. In the era of precision medicine, emerging knowledge on molecular endometrial carcinosarcoma is opening new promising therapeutic options for more personalized treatment. The present review outlines state-of-the-art knowledge and future directions for patients with endometrial carcinosarcoma.

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77dda5897663198659e24d76768fe02cTest
https://hdl.handle.net/10807/232465Test

المؤلفون: Serena Cappuccio, Riccardo Oliva, Claudia Marchetti, Barbara Costantini, Gianfranco Zannoni, Giovanni Scambia, Anna Fagotti

المصدر: Ovarian cancer.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::034bd08e26e06cfc45ba858ba195b5b8Test
https://doi.org/10.1136/ijgc-2022-esgo.603Test

المؤلفون: Lil Valentin, Dorella Franchi, Giovanni Scambia, Daniela Fischerova, A. C. Testa, L. M. Castellano, D. Timmerman, Elisabeth Epstein, Gianfranco Zannoni, Francesca Moro, Wouter Froyman, Floriana Mascilini

المصدر: Ultrasound in Obstetrics & Gynecology. 57:987-994

مصطلحات موضوعية: Adult, Pathology, medicine.medical_specialty, Adolescent, Databases, Factual, Malignant Germ Cell Tumor, Embryonal, Embryonal carcinoma, Ovarian Choriocarcinoma, Young Adult, Non-gestational, Databases, Ovarian tumor, Carcinoma, Embryonal, Neoplasms, Malignant Ovarian Germ Cell Tumor, medicine, Humans, Radiology, Nuclear Medicine and imaging, Choriocarcinoma, germ cell tumors, Factual, Aged, Retrospective Studies, Ultrasonography, Ovarian Neoplasms, Radiological and Ultrasound Technology, business.industry, Carcinoma, Choriocarcinoma, Non-gestational, Obstetrics and Gynecology, Echogenicity, ultrasonography, General Medicine, ovarian neoplasms, Middle Aged, Neoplasms, Germ Cell and Embryonal, medicine.disease, Women's Health Services, Settore MED/40 - GINECOLOGIA E OSTETRICIA, Italy, Reproductive Medicine, Germ Cell and Embryonal, Female, Germ cell tumors, business

الوصف: OBJECTIVE: To describe the clinical and ultrasound characteristics of three types of rare malignant ovarian germ cell tumor: embryonal carcinoma, non-gestational choriocarcinoma and malignant mixed germ cell tumor. METHODS: This was a retrospective multicenter study. From the International Ovarian Tumor Analysis (IOTA) database, we identified patients with a histological diagnosis of ovarian embryonal carcinoma, non-gestational choriocarcinoma or malignant mixed germ cell tumor, who had undergone preoperative ultrasound examination by an experienced ultrasound examiner between 2000 and 2020. Additional patients with the same histology were identified from the databases of the departments of gynecological oncology in the participating centers. All tumors were described using IOTA terminology. Three examiners reviewed all available ultrasound images and described them using pattern recognition. RESULTS: One patient with embryonal carcinoma, five patients with non-gestational ovarian choriocarcinoma and seven patients with ovarian malignant mixed germ cell tumor (six primary tumors and one recurrence) were identified. Seven patients were included in the IOTA studies and six patients were examined outside of the IOTA studies. The median age at diagnosis was 26 (range, 14-77) years. Beta-human chorionic gonadotropin levels were highest in non-gestational choriocarcinomas and alpha-fetoprotein levels were highest in malignant mixed germ cell tumors. Most tumors were International Federation of Gynecology and Obstetrics (FIGO) Stage I (9/12 (75.0%)). All tumors were unilateral, and the median largest diameter was 129 (range, 38-216) mm. Of the tumors, 11/13 (84.6%) were solid and 2/13 (15.4%) were multilocular-solid; 9/13 (69.2%) manifested abundant vascularization on color Doppler examination. Using pattern recognition, the typical ultrasound appearance was a large solid tumor with inhomogeneous echogenicity of the solid tissue and often dispersed cysts which, in most cases, were small and irregular. Some tumors had smooth contours while others had irregular contours. CONCLUSIONS: A unilateral, large solid tumor with inhomogeneous echogenicity of the solid tissue and with dispersed small cystic areas in a young woman should raise the suspicion of a rare malignant germ cell tumor. This suspicion can guide the clinician to test tumor markers specific for malignant germ cell tumors. © 2020 International Society of Ultrasound in Obstetrics and Gynecology. ispartof: ULTRASOUND IN OBSTETRICS & GYNECOLOGY vol:57 issue:6 pages:987-994 ispartof: location:England status: published

وصف الملف: Print

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93866363cb8db0dc8d3f2cb18126e653Test
https://doi.org/10.1002/uog.23529Test

المؤلفون: Giovanni Scambia, Damiano Aciuolo, Camilla Fedele, Anna Franca Cavaliere, Gianfranco Zannoni, Annalisa Vidiri, Maria Vittoria Carbone

المصدر: European Journal of Obstetrics & Gynecology and Reproductive Biology. 256:326-332

مصطلحات موضوعية: Uterine tumor resembling ovarian cord tumor, medicine.medical_specialty, Gonadal cord, media_common.quotation_subject, Fertility sparing, Fertility, World health, Fertility sparing surgery, 03 medical and health sciences, 0302 clinical medicine, Biomarkers, Tumor, medicine, Humans, Sex Cord-Gonadal Stromal Tumors, Childbirth, 030212 general & internal medicine, Radical surgery, media_common, Ovarian Neoplasms, 030219 obstetrics & reproductive medicine, business.industry, Obstetrics and Gynecology, Cancer, medicine.disease, Immunohistochemistry, Surgery, Uterine Tumor, Settore MED/40 - GINECOLOGIA E OSTETRICIA, Reproductive Medicine, Uterine Neoplasms, Sex cord stromal endometrial cancer, Female, UTROSCT, business

الوصف: Uterine tumor resembling ovarian sex-cord tumor (UTROSCT) is a rare distinct cancer included in the current World Health Organization classification of endometrial stromal tumors. A battery of immunohistochemical markers are necessary for accurate diagnosis. Although few case reports and case series have been documented and therefore providing robust prognostic information several authors agree to consider UTROSCT as a low malignant potential tumour. In literature only five cases of conservative management were reported. We reported our experience and a review of conservative cases of literature. In this article we describe a series of 10 cases of UTROSCT and their clinical and pathologic feature. We report two cases of conservative surgical approach obtaining a successfully pregnancies. All of the patients are still alive. In conclusion, fertility sparing surgery should be offered to patients who wish preserve their fertility however radical surgery must be considerate after childbirth. Close follow-up is required for all patients due to the lack of prognostic biomarkers and long follow up is needed to evaluate safety of conservative surgery.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10c570bc1297d44afee06201a7dbf339Test
https://doi.org/10.1016/j.ejogrb.2020.11.043Test